Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead: Results From APOLLO Prospective Multicenter Study
BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy relies on reliable right ventricular leads for pacing, sensing, and defibrillation. The INVICTA DF4 lead is an active-fixation, quadripolar design intended to optimize implant workflow and long-term safety and performance. METHODS: APOLLO was a prospective, multicenter, single-arm, observational study enrolling adults across Europe with guideline-based indications for de novo ICD or Cardiac Resynchronization Therapy Defibrillator (CRT-D) implantation who received an INVICTA DF4 lead (single- or dual-coil; 58 or 68 cm). The co-primary endpoints focused on safety and performance at 3 months, while secondary endpoints included long-term electrical variables, arrhythmia termination, and lead-related complications through 24 months. RESULTS: Between June 4, 2021, and October 19, 2022, 446 patients were implanted across 45 sites in 8 European countries. The INVICTA lead was successfully implanted in 100% of the 446 enrolled patients. Leads were positioned either in the apex in 57.2% or right ventricle (RV) septum in 42.8%. Electrical variables stabilized after discharge and remained stable up to 24 months (M24 mean pacing threshold 0.85 ± 0.33 V at 0.5 ms; sensing 13.39 ± 3.17 mV; pacing impedance 525.5 ± 94.2 Ohms; right ventricular (RV) coil continuity 427.8 ± 82.7 Ohms). Of 86 arrhythmic episodes requiring defibrillation, 97.7% were successfully terminated. Lead-related complication free rate was 97.5% at 30 days, 98.9% at 31-730 days, and 96.4% overall. Mortality was 8.5% (38/446) at two years, of which 63% was due to cardiovascular causes. CONCLUSIONS: In a large, contemporary European cohort, the INVICTA DF4 ventricular lead demonstrated high implant success, durable electrical performance, effective arrhythmia termination, and low complication rates through 24 months. A trend toward less complication in septal positioning was observed compared to apical placement, with comparable electrical performance.
Authors
- Antoine Dompnier (ORCID: https://orcid.org/0000-0002-1960-3392)
- Maite Izquierdo (ORCID: https://orcid.org/0000-0003-0599-1336)
- Cosimo Mandurino
- José Juan García Salvador
- P M Pedro Marques
- Mario M. Oliveira
- K K Witte
- Pablo J. Sánchez Millán
- Maria Martino
- Alberto Barrera
- Carsten Israel
- Juan Gabriel Martínez (ORCID: https://orcid.org/0000-0003-2255-3530)
- Frédéric Jean
- Maria Emilce Trucco
Institutions
- University of Leeds (GB)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Centro Medicina della Riproduzione (IT)
- Evangelisches Krankenhaus Bielefeld (DE)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Hospital Universitario Virgen de las Nieves (ES)
- Universitätsklinikum Aachen (DE)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre Hospitalier Annecy Genevois (FR)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Hospital de Santa Maria (PT)
- Ospedale SS. Annunziata (IT)
- Hospital Universitari de Girona Doctor Josep Trueta (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
Publication Details
- Journal
- Pacing and Clinical Electrophysiology
- Published
- 2026-05-16
- DOI
- https://doi.org/10.1111/pace.70286
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00